Camurus
Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.
DitchCarbon Score
How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Camurus's score of 16 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Camurus's reported carbon emissions
In 2023, Camurus reported total carbon emissions of approximately 561,800 kg CO2e. This figure includes 158,900 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 11,680 kg CO2e from Scope 2 emissions. Notably, Scope 3 emissions accounted for about 385,600 kg CO2e, with significant contributions from downstream transportation and distribution, which alone contributed approximately 287,714 kg CO2e. In comparison, the previous year, 2022, Camurus's total emissions were about 231,600 kg CO2e, with Scope 1 emissions at 162,400 kg CO2e and Scope 2 emissions at 16,690 kg CO2e. The Scope 3 emissions for that year were approximately 60,300 kg CO2e. Despite the increase in total emissions from 2022 to 2023, there are currently no publicly disclosed reduction targets or climate pledges from Camurus. The company operates within the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction initiatives. As such, Camurus's commitment to addressing its carbon footprint remains a critical area for future development.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 162,400 | 000,000 |
| Scope 2 | 8,990 | 00,000 |
| Scope 3 | 60,300 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Camurus is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
